The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Comprehensive characterization of monoclonal antibody by Fourier transform ion cyclotron resonance mass spectrometry
Open accessAbstract
The pharmaceutical industry's interest in monoclonal antibodies (mAbs) and their derivatives has spurred rapid growth in the commercial and clinical pipeline of these effective therapeutics. The complex micro-heterogeneity of mAbs requires in-depth structural characterization for critical quality attribute assessment and quality assurance. Currently, mass spectrometry (MS)-based methods are the gold standard in mAb analysis, primarily with a bottom-up approach in which immunoglobulins G (IgGs) and their variants are digested into peptides to facilitate the analysis. Comprehensive characterization of IgGs and the micro-variants remains challenging at the proteoform level. Here, we used both top-down and middle-down MS for in-depth characterization of a human IgG1 using ultra-high resolution Fourier transform MS. Our top-down MS analysis provided characteristic fingerprinting of the IgG1 proteoforms at unit mass resolution. Subsequently, the tandem MS analysis of intact IgG1 enabled the detailed sequence characterization of a representative IgG1 proteoform at the intact protein level. Moreover, we used the middle-down MS analysis to characterize the primary glycoforms and micro-variants. Micro-variants such as low-abundance glycoforms, C-terminal glycine clipping, and C-terminal proline amidation were characterized with bond cleavages higher than 44% at the subunit level. By combining top-down and middle-down analysis, 76% of bond cleavage (509/666 amino acid bond cleaved) of IgG1 was achieved. Taken together, we demonstrated the combination of top-down and middle-down MS as powerful tools in the comprehensive characterization of mAbs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Undoubtedly, the advancement of top-down proteomics is stimulated by the commercial growth of large molecule therapeutics such as monoclonal antibodies and antibody-drug-conjugates as detailed and high-throughput methods for their characterization and quality control are required [81,159,160].”
From Top-down proteomics: challenges, innovations, and applications in basic and clinical research (2020) · cites this paper as [160]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proteoform: a single term describing protein complexity
The Consortium for Top Down Proteomics, Smith, L. M., & Kelleher, N. L. (2013) · Nature Methods · doi:10.1038/nmeth.2369 · Cited by 1,528
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,286
Antibody Structure, Instability, and Formulation
Wang, W., Singh, S., Zeng, D. L., King, K., & Nema, S. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20727 · Cited by 941
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754 · cited 3×
“Currently, over 550 mAb candidates and their derivatives are in the clinical development stage.(1) The high selectivity and specificity towards given targets led to the success of antibody-based drugs in the treatment of a variety of diseases including cardiovascular, infectious, immunological diseases and cancer.”
BackgroundBuilding better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Characterization of Therapeutic Antibodies and Related Products
Beck, A., Wagner-Rousset, E., Ayoub, D., Van Dorsselaer, A., & Sanglier-Cianférani, S. (2013) · Analytical Chemistry · doi:10.1021/ac3032355 · Cited by 587 · cited 2×
“A unit mass resolution was achieved in our top-down MS analysis of intact IgG1, allowing the identification of six different IgG1 glycoforms at one specific charge state and clearly shows the glycosylation pattern of IgG1, which is consistent with the reported information in previous studies.(36) The comprehensive ana…”
BackgroundResultDecoding protein modifications using top-down mass spectrometry
Siuti, N., & Kelleher, N. L. (2007) · Nature Methods · doi:10.1038/nmeth1097 · Cited by 503
Heterogeneity of Monoclonal Antibodies
Liu, H., Gaza-Bulseco, G., Faldu, D., Chumsae, C., & Sun, J. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21180 · Cited by 481
Precision proteomics: The case for high resolution and high mass accuracy
Mann, M., & Kelleher, N. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800788105 · Cited by 450 · cited 1×
“High mass accuracy from isotopically resolved high-resolution MS data could be used to increase the confidence level of protein identification with detection of PTMs and variations in sequence.(35) The glycosylation pattern of an intact mAb including other low-abundance glycoforms has never been isotopically resolved…”
Background
Cited by
Top-down proteomics: challenges, innovations, and applications in basic and clinical research
Brown, K. A., Melby, J. A., Roberts, D. S., & Ge, Y. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1855982 · Cited by 152
Self-citationSrzentić, K., Fornelli, L., Tsybin, Y. O., Loo, J. A., Seckler, H. S., Agar, J. N., Anderson, L. C., Bai, D. L., Beck, A., Brodbelt, J. S., et al. (2020) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.0c00036 · Cited by 131
Self-citationIon Activation Methods for Peptides and Proteins
Macias, L. A., Santos, I. C., & Brodbelt, J. S. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b04859 · Cited by 107
Grassi, L., & Cabrele, C. (2019) · Amino Acids · doi:10.1007/s00726-019-02787-2 · Cited by 111
Middle-down approach: a choice to sequence and characterize proteins/proteomes by mass spectrometry
Pandeswari, P. B., & Sabareesh, V. (2019) · RSC Advances · doi:10.1039/c8ra07200k · Cited by 99
Metadata
- Authors
- Jin, Y., Lin, Z., Xu, Q., Fu, C., Zhang, Z., Zhang, Q., Pritts, W. A., & Ge, Y.
- Affiliations
- University of Wisconsin–Madison (US)
- AbbVie (United States) (US)
- Corresponding author
- Ge, Ying
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2018-12-22
- Volume
- 11
- Issue
- 1
- Pages
- 106-115
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- PMC
- PMC6343775
- OpenAlex
- W2890820905
- Cited by
- 68
- References
- 49
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 9 · 2023: 12 · 2022: 13 · 2021: 5 · 2020: 10 · 2019: 7
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- mAbs (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1R01GM117058-01, 5R01HL096971-05, 5R01HL109810-03, 1S10OD018475-01)
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- monoclonal antibodies, IgG1, top-down mass spectrometry, middle-down mass spectrometry, proteoforms, glycoforms, bond cleavage, critical quality attributes
- MeSH terms
- Antibodies, Monoclonal, Fourier Analysis, Humans, Cyclotrons, Tandem Mass Spectrometry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive characterization of monoclonal antibody by Fourier transform ion cyclotron resonance mass spectrometry. https://app.cochat.ai/papers/10.1080/19420862.2018.1525253
- The paper
- Jin, Y., Lin, Z., Xu, Q., Fu, C., Zhang, Z., Zhang, Q., Pritts, W. A., & Ge, Y. (2019). Comprehensive characterization of monoclonal antibody by Fourier transform ion cyclotron resonance mass spectrometry. mAbs. https://doi.org/10.1080/19420862.2018.1525253
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.